Informasi edukatif, bukan saran investasi
Ekonomi penyuntingan gen
Bagaimana industri ini dibiayai, untuk apa uang itu sebenarnya digunakan, dan mengapa keberhasilan klinis sangat sulit diprediksi.
Perusahaan publik
Perusahaan pengeditan gen dengan saham tercatat di CRISPR Decoded. Kami tidak menyediakan data pasar langsung, angka seperti kapitalisasi pasar berubah terus-menerus, sehingga kami mengarahkan Anda ke sumber utama daripada menampilkan angka yang sudah tidak akurat saat Anda membacanya.
| Perusahaan | Ticker | Pertukaran | Kantor Pusat | Platform | Tahap utama |
|---|---|---|---|---|---|
| CRISPR Therapeutics | CRSP | Nasdaq | Zug, Switzerland | CRISPR-Cas9 platform | Approved |
| Intellia Therapeutics | NTLA | Nasdaq | Cambridge, Massachusetts | In vivo CRISPR platform | Phase III |
| Beam Therapeutics | BEAM | Nasdaq | Cambridge, Massachusetts | Base editing platform | Phase III |
| Editas Medicine | EDIT | Nasdaq | Cambridge, Massachusetts | In vivo editing | Preclinical |
| Prime Medicine | PRME | Nasdaq | Cambridge, Massachusetts | Prime editing platform | Phase I/II |
| Caribou Biosciences | CRBU | Nasdaq | Berkeley, California | Cell therapy | Phase I |
| Sana Biotechnology | SANA | Nasdaq | Seattle, Washington | Cell engineering | Phase I |
| Vertex Pharmaceuticals | VRTX | Nasdaq | Boston, Massachusetts | Large biotechnology | Approved |
| Sangamo Therapeutics | SGMO | Nasdaq | Richmond, California | Zinc finger platform | Phase III |
| Eli Lilly and Company | LLY | NYSE | Indianapolis, Indiana | Large pharmaceutical | Phase II |
Perusahaan swasta
Didukung modal ventura dan dimiliki secara privat. Angka pendanaan berasal dari pengumuman perusahaan dan diberi tanggal di setiap profil.
Boston, Massachusetts
Verve Therapeutics
Built to turn heart disease into a one-time treatment, and acquired by Eli Lilly in 2025…
Diperoleh: Acquired by Eli Lilly for ~$1 billion plus CVR
Alameda, California
Scribe Therapeutics
Co-founded by Jennifer Doudna to engineer CRISPR enzymes from scratch rather than use the…
Brisbane, California
Mammoth Biosciences
Co-founded by Jennifer Doudna around ultra-compact CRISPR proteins small enough to fit…
Cambridge, Massachusetts
Arbor Biotechnologies
Co-founded by Feng Zhang and David Scott to discover new editing enzymes from nature at…
Somerville, Massachusetts
bluebird bio
A pioneer of lentiviral gene addition with several approved therapies, and a cautionary…
Somerville, Massachusetts
Tessera Therapeutics
Developing 'gene writing': mobile genetic elements repurposed to insert whole sequences…
Durham, North Carolina
Tune Therapeutics
Turning genes up and down without changing sequence: epigenetic editing taken into early…
Daftar industri
Memahami aspek ekonomi
Mengapa pengobatan satu kali menjadi bisnis yang sulit, berapa nilai priority review voucher, dan bagaimana harga terapi gen ditentukan.
Berita perusahaan, pendanaan, dan kesepakatan
Dari penerbit terverifikasi; setiap judul tertaut ke sumber aslinya.
STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
Where should the safety bar be for studies investigating CAR-T therapies for autoimmune conditions?
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
A patient has died in a Bristol Myers Squibb study of autoimmune CAR-T, the same technology that was called into question this summer when both Bristol…
Merck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3B
Germany's Merck KGaA agreed to buy UK drug developer Silence Therapeutics for $1.3 billion, building out its work in rare and specialty diseases using…
ADC Development from Concept to Clinic
This eBook brings insight on integrated end-to-end solutions for precision engineered therapeutics. The post ADC Development from Concept to Clinic…
Estuary debuts with $103M to develop kidney disease gene therapies
Estuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most…
Parkinson's cell therapy biotech Aspen and I&I startup Bambusa file for IPOs
A Gilead-backed cell therapy maker and an I&I biotech from BioNTech vets are looking to ride the biotech industry's IPO momentum. Aspen Neuroscience and…
Di mana mendapatkan angka yang tidak kami tampilkan
Pengajuan perusahaan
Untuk perusahaan yang terdaftar di AS, sistem SEC EDGAR menyimpan laporan tahunan (10-K) dan kuartalan (10-Q), termasuk posisi kas dan biaya operasional, dua angka yang paling penting bagi perusahaan bioteknologi yang belum menghasilkan pendapatan.
Status uji klinis
ClinicalTrials.gov adalah registri resmi untuk studi yang terdaftar di Amerika Serikat, mencakup tanggal mulai, pendaftaran peserta, dan hasil yang dipublikasikan.
Keputusan regulasi
Surat persetujuan FDA dan laporan penilaian EMA menyatakan dengan tepat apa yang disetujui, untuk siapa, dan berdasarkan bukti apa, jauh lebih rinci dibandingkan ringkasan mana pun.